Patent US5885601A successfully refreshed from Google Patents.
US5885601A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of macrolide antibiotics for nonsurgical female sterilization and endometrial ablation
Assignee: Family Health International 360
•
Filing: 1997-04-04
•
Granted: 1999-03-23
•
Expires: 2017-04-04
Abstract
Abstract The present invention relates to a method of female sterilization including delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic to the uterine cavity or fallopian tube of the female. The present invention also relates to a method of endometrial ablation including delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic to the uterine cavity of a female. The endometrial ablation effected in this manner may be used to treat the conditions of excessive menstrual bleeding or menstrual pain in women. A preferred macrolide antibiotic is erythromycin, or its pharmacologically acceptable salts.
Inventors
- 👤 David C. Sokal
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 19:31
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7042; A61K31/7048; A61K33/00; A61K33/24; A61K33/34; A61K38/00; A61K38/04; A61K38/08; A61K38/09; A61K45/00; A61K45/06; A61K9/00; A61K9/0012; A61K9/0034
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
38 words
A method of female sterilization comprising delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic directly to the uterine cavity or fallopian tube of the female in an amount effective to cause sterilization.
Claim 2
Independent Claim
38 words
A method of female sterilization comprising delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic directly to the uterine cavity or fallopian tube of the female in an amount effective to cause sterilization.
Claim 3
Dependent Claim
11 words
The method of claim 1, wherein the female is a mammal.
Claim 4
Dependent Claim
22 words
The method of claim 1, wherein the macrolide antibiotic is selected from the group consisting of erythromycin, spiramycin, clarithromycin, roxithromycin, and azithromycin.
Claim 5
Dependent Claim
20 words
The method of claim 1, wherein the macrolide antibiotic is erythromycin A or a pharmacologically acceptable salt of erythromycin A.
Claim 6
Dependent Claim
29 words
The method of claim 1, wherein the pharmacologically acceptable salt is selected from the group consisting of erythromycin gluceptate, erythromycin lactobionoate, erythromycin stearate, erythromycin estolate, and erythromycin ethyl succinate.
Claim 7
Dependent Claim
32 words
The method of claim 3, wherein the macrolide antibiotic or its pharmologically acceptable salt, is delivered in a dosage which is equivalent to about 50 to about 1000 milligrams of erythromycin base.
Claim 8
Dependent Claim
19 words
The method of claim 1, wherein the macrolide antibiotic or its pharmacologically acceptable salt is delivered in sequential stages.
Claim 9
Dependent Claim
27 words
The method of claim 1, comprising administration of the macrolide antiobiotic or its pharmacologically acceptable salt to the uterine fundus without requiring localization near the tubal ostia.
Claim 10
Dependent Claim
22 words
The method of claim 1, wherein the macrolide antibiotic or its pharmacologically acceptable salt is delivered as a powder, gel, or suspension.
Claim 11
Dependent Claim
20 words
The method of claim 1, wherein the macrolide antibiotic or its pharmacologically acceptable salt is delivered as a solid pellet.
Claim 12
Dependent Claim
26 words
The method of claim 1, further comprising the administration of an adjuvant selected from the group consisting of hormonal agents, antiprostaglandins, steroidal compounds, and combinations thereof.
Claim 13
Dependent Claim
27 words
The method of claim 1, further comprising the administration of an adjuvant selected from the group consisting of copper, betamethasone, ibuprofen, depot-medroxyprogesterone, goserelin, danazol, and combinations thereof.
Claim 14
Independent Claim
31 words
A method of endometrial ablation comprising delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic directly to the uterine cavity or fallopian tube of a female.
Claim 15
Independent Claim
31 words
A method of endometrial ablation comprising delivery of a macrolide antibiotic or a pharmacologically acceptable salt of a macrolide antibiotic directly to the uterine cavity or fallopian tube of a female.
Claim 16
Dependent Claim
11 words
The method of claim 13, wherein the female is a mammal.
Claim 17
Dependent Claim
22 words
The method of claim 13, wherein the macrolide antibiotic is selected from the group consisting of erythromycin, spiramycin, clarithromycin, roxithromycin, and azithromycin.
Claim 18
Dependent Claim
20 words
The method of claim 13, wherein the macrolide antibiotic is erythromycin A or a pharmacologically acceptable salt of erythromycin A.
Claim 19
Dependent Claim
29 words
The method of claim 13, wherein the pharmacologically acceptable salt is selected from the group consisting of erythromycin gluceptate, erythromycin lactobionoate, erythromycin stearate, erythromycin estolate, and erythromycin ethyl succinate.
Claim 20
Dependent Claim
17 words
The method of claim 13, wherein said endometrial ablation prevents or reduces menstrual bleeding in the female.
Claim 21
Dependent Claim
17 words
The method of claim 13, wherein said endometrial ablation prevents or reduces menstrual pain in the female.
Claim 22
Dependent Claim
21 words
The method of claim 13, wherein the erythromycin or its pharmacologically acceptable salt is delivered as a powder, gel, or suspension.
Claim 23
Dependent Claim
18 words
The method of claim 13, wherein the erythromycin or its pharmacologically acceptable salt is delivered as a pellet.
Claim 24
Dependent Claim
28 words
The method of claim 13, wherein the erythromycin or its pharmacologically acceptable salt is delivered in an amount effective to prevent or reduce menstrual bleeding in the female.
Claim 25
Dependent Claim
28 words
The method of claim 13, wherein the erythromycin or its pharmacologically acceptable salt is delivered in an amount effective to prevent or reduce menstrual pain in the female.
Claim 26
Dependent Claim
26 words
The method of claim 13, further comprising the administration of an adjuvant selected from the group consisting of hormonal agents, antiprostaglandins, steroidal compounds, and combinations thereof.
Claim 27
Dependent Claim
27 words
The method of claim 13, further comprising the administration of an adjuvant selected from the group consisting of copper, betamethasone, ibuprofen, depot-medroxyprogesterone, goserelin, danazol, and combinations thereof.
Claim 28
Dependent Claim
20 words
The method of claim 13, wherein the macrolide antibiotic or pharmacologically acceptable salt thereof is administered by a non-surgical method.
Claim 29
Dependent Claim
20 words
The method of claim 1, wherein the macrolide antibiotic or pharmacologically acceptable salt thereof is administered by a non-surgical method.
Claim 30
Dependent Claim
20 words
The method of claim 6, wherein the dosage is equivalent from about 250 to about 500 milligrams of erythromycin base.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-03-22 | 2002-09-21 | 2003-03-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-03-22 | 2006-09-21 | 2007-03-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-03-22 | 2010-09-21 | 2011-03-23 | $7700.00 | Window Closed / Lapsed |